2 ASX 200 healthcare shares that outperformed in November 

ASX 200 healthcare shares finished flat for November, but there were a few sector players that shrugged off the weakness and outperformed.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The S&P/ASX 200 Health Care Index (ASX: XHJ) finished November just 2.72% higher compared to the 9.5% surge in the S&P/ASX 200 Index (ASX: XJO). Sectors that benefitted from lockdowns including technology, ecommerce and consumer staples underperformed in November, while beaten up sectors such as financials, travel and real estate did the heavy lifting for the index.

ASX 200 healthcare heavyweights flat in November 

ASX 200 healthcare shares that dominate the index weightings finished relatively flat in November. The CSL Limited (ASX: CSL) share price closed 4% higher, the Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) share price was down just 1.25%, Sonic Healthcare Ltd (ASX: SHL) was the worst performing, down almost 6% and Cochlear Ltd (ASX: COH) shares finished up by only 2.5%. 

The underperformance of these heavyweights reiterate the rotation narrative into cyclicals and value stocks, and the recent fallout of stocks that benefitted from the lockdowns and COVID-19

Despite the flat performance, there were some hidden gems in the ASX 200 that delivered significant returns. 

Another crazy month for Mesoblast Limited (ASX: MSB)

It's been a wild ride for Mesoblast shares as the biotech continues its research while burning through cash. Previously, the Mesoblast share price crashed 40% after the United States Food and Drug Administration did not approve its highly anticipated Remestemcel-L treatment and advised an additional randomised controlled study. 

Rather than moving into the much needed commercialisation of its treatment, the company was sent packing to undertake additional study. This saw the Mesoblast share price nose dive more than 40% on 2 October. 

Its shares have since turned around to surge 35% in November. This follows the company's exclusive worldwide license and collaboration agreement with Novartis for the development, manufacture and commercialisation of its mesenchymal stromal cell (MSC) product, Remestemcel-L. 

The initial focus will be on the development of the treatment of acute respiratory distress syndrome (ARDS), including that associated with COVID-19. 

From a revenue perspective, Novartis will make an upfront US$50 million payment including US$25 million in equity. Mesoblast may receive a total of US$505 million pending achievement of pre-commercialisation milestones for ARDS indications. 

Polynovo Ltd (ASX: PNV) soars on expansion and sales growth 

The Polynovo share price pushed 30% higher in November into record territory. The company is experiencing a rapid increase in revenue as it commercialises its NovoSorb BTM product globally. 

When trauma to the skin occurs, large portions of the surface of the skin and its deeper layers are destroyed. NovoSorb BTM may be used to temporarily close the wound and aid the body in generating new tissue.

NovoSorb sales increased from $9.3 million in FY19 to $19.06 million in FY20. More recently, the company has been expanding its presence and growing its sales team across Europe and Asia. 

Lina Lim has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd., CSL Ltd., and POLYNOVO FPO. The Motley Fool Australia has recommended Cochlear Ltd. and Sonic Healthcare Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Ten smiling business people wave to the camera after receiving some winning company news.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a nervous, but positive, Tuesday for ASX investors.

Read more »

two colleagues high five each other as they sit side by side at a long desk in front of their laptop computers in an office environment.
Share Gainers

Why Bapcor, Ramelius, Sandfire, and WIA Gold shares are rising today

These shares are having a better day than most on Tuesday. But why?

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors started the week off in a good mood today.

Read more »

Excited couple celebrating success while looking at smartphone.
Share Gainers

Why Bellevue Gold, Bubs, Clarity Pharmaceuticals, and Regal Partners shares are rising today

These shares are starting the week on a positive note.

Read more »

Two people lazing in deck chairs on a beautiful sandy beach throw their hands up in the air.
Travel Shares

Guess which ASX All Ords travel stock just rocketed 17% on an earnings upgrade

Investors are piling into the ASX All Ords travel stock today. Here's what's happening.

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords stock just rocketed 34% on strong earnings growth

Investors just sent this ASX All Ords stock surging 34%. Here’s what’s happening.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Dimerix, Newmont, Regal Partners, and Titomic shares are storming higher

These shares are having a good finish to the week. Let's see why.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why Fortescue, Lynas, PEXA, and Regis Healthcare shares are charging higher

These shares are having a strong session on Thursday. But why?

Read more »